Equitec Proprietary Markets, LLC Alaunos Therapeutics, Inc. Transaction History

Equitec Proprietary Markets, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$1.09 - $1.89 $11,995 - $20,799	-11,005 Reduced 91.49%	1,023 $1,000
Q2 2021 Jul 20, 2021	BUY	$2.63 - $3.67 $18,546 - $25,880	7,052 Added 141.72%	12,028 $32,000
Q4 2020 Jan 26, 2021	SELL	$2.09 - $3.09 $4,021 - $5,945	-1,924 Reduced 27.88%	4,976 $13,000
Q3 2020 Oct 13, 2020	BUY	$2.39 - $3.43 $5,669 - $8,135	2,372 Added 52.39%	6,900 $17,000
Q1 2020 Apr 19, 2021	SELL	$1.9 - $4.98 $30,046 - $78,753	-15,814 Reduced 77.74%	4,528 $16,000
Q1 2018 May 23, 2018	SELL	$3.46 - $5.14 $151,385 - $224,890	-43,753 Reduced 68.26%	20,342 $80,000
Q4 2017 Jan 24, 2018	BUY	$4.0 - $6.54 $14,492 - $23,694	3,623 Added 5.99%	64,095 $265,000
Q3 2017 Oct 23, 2017	BUY	$4.99 - $6.57 $301,755 - $397,301	60,472	60,472 $371,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Equitec Proprietary Markets, LLC, based on Form 13F filings with the SEC.

Stay updated on Equitec Proprietary Markets, LLC with notifications on news.